Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul-Aug;136(4):354-360.
doi: 10.1590/1516-3180.0271250618. Epub 2018 Aug 20.

What do Cochrane systematic reviews say about interventions for treating psoriasis?

Affiliations
Review

What do Cochrane systematic reviews say about interventions for treating psoriasis?

Rafael Leite Pacheco et al. Sao Paulo Med J. 2018 Jul-Aug.

Abstract

Context and objective: Psoriasis is a common chronic inflammatory skin disease characterized by abnormal and increased growth of the cells that produce keratin and abnormal functioning of the immune system. We aimed to summarize the evidence available regarding interventions for patients with psoriasis.

Design and setting: Review of systematic reviews, developed in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo.

Methods: A systematic search was conducted to identify Cochrane systematic reviews that fulfilled the eligibility criteria. Two authors screened titles and abstracts that had been retrieved through the search strategy. The results from all the Cochrane systematic reviews that were included were summarized and presented in a narrative synthesis.

Results: We included six Cochrane systematic reviews assessing interventions for treating psoriasis. The findings from high-quality evidence were that (a) etanercept reduced the psoriasis severity index, compared with placebo and (b) steroids plus vitamin D, compared with vitamin D alone, improved the skin clearance rate, as assessed by investigators, but was associated with a higher proportion of participants who dropped out due to adverse events. For all other comparisons, the quality of the evidence ranged from moderate to very low.

Conclusion: This review included six Cochrane systematic reviews that provided evidence ranging in quality from unknown to high, regarding management of psoriasis. Further randomized controlled trials are imperative to reduce the uncertainties relating to several treatments that are already used in clinical practice.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None

Figures

Figure 1:
Figure 1:. Number of studies indexed with “Psoriasis”[Mesh], published per year since 1963.

Similar articles

References

    1. Parisi R, Symmons DP, Griffiths CE. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339. - DOI - PubMed
    1. Fairhurst DA, Ashcroft DM, Griffiths CEM. Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol. 2005;6(5):283–294. doi: 10.2165/00128071-200506050-00002. - DOI - PubMed
    1. da Silva CAP, Von Kossel K, Leszczynski M, Melnik T, Riera R. Methotrexate for psoriasis (Protocol) Cochrane Database of Syst Rev. 2013;4:CD010498–CD010498. doi: 10.1002/14651858.CD010498. - DOI
    1. Tagami H. Triggering factors. Clin Dermatol. 1997;15(5):677–685. doi: 10.1016/S0738-081X(97)00024-2. - DOI - PubMed
    1. Carretero G, Puig L, Dehesa L. Metotrexato Guia de uso en psoriasis [Guidelines on the use of methotrexate in psoriasis]. Actas Dermosifiliogr. 2010;101(7):600–613. doi: 10.1016/j.ad.2010.04.002. - DOI - PubMed